MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer
| Autor: | Baoping Zhai, Wentao Li, Pilei Si, Haijun Chen, Cao Wang, Jinjin Shi, Xuefang Mi, Pei Zhang, Wenling Chu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Drug Cancer Research Cell Survival Aptamer media_common.quotation_subject medicine.medical_treatment Breast Neoplasms 03 medical and health sciences DNA Adducts 0302 clinical medicine Breast cancer Drug Delivery Systems In vivo medicine Humans Doxorubicin Breast media_common Cell Proliferation Chemotherapy Drug Carriers Chemistry Mucin-1 Mesoporous silica medicine.disease Gene Expression Regulation Neoplastic Drug Liberation 030104 developmental biology Oncology 030220 oncology & carcinogenesis Drug delivery Cancer research MCF-7 Cells Nanoparticles Female medicine.drug |
| Zdroj: | Cancer letters. 472 |
| ISSN: | 1872-7980 |
| Popis: | Tumor-targeted drug delivery systems with stimuli-response drug release have been increasingly used to improve the therapeutic efficacy of antitumor drugs. Here, we report a specific molecular recognition activation drug nanoplatform based on specially designed DNA sensor-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs), designated as specific molecular recognition-activated nanoparticle (SMRAN). DNA sensors on the targeted nanoparticles can trigger DOX release through a conformational switch induced by MUC-1. This causes a significant difference in cell viability between breast cancer MCF-7 and normal breast Hs578bst cells (24.8% and 86.0%). In vivo experiments showed that the tumor volume was reduced 1.5-times in the SMRAN treatment group. Compared with that in the DOX group, due to significantly improved tumor accumulation and retention of DOX. The strategy of the MUC-1 activated drug delivery system is expected to provide a new perspective for clinical application. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect